What to Know

Learn more about what Meitheal Pharmaceuticals is doing to deliver on its vision of Healthcare Solutions within reach.

Watch Video

Stories that should have your attention

Certain items require a place in the Spotlight. This section will provide updates that we want to make sure are seen by our current and future partners alike.

Bookmark and visit this page for updates and news you can use to be an even more informed and aware partner, patient, employee or physician.

Meitheal Pharmaceuticals Secures Exclusive Commercial Licensing Agreement for Three Biosimilars in the U.S.

Spotlight

Meitheal Pharmaceuticals Expands Specialty Biopharmaceuticals Portfolio with Acquisition of CONTEPO™ (Fosfomycin for Injection) from Nabriva Therapeutics

Spotlight

Meitheal Pharmaceuticals Announces Exclusive Commercial Licensing Agreement for YUSIMRY®

Spotlight

Meitheal Pharmaceuticals Announces Recent Business Progress Reinforcing Commitment to Sustainable Generics Development

Spotlight

Meitheal Pharmaceuticals Joins Biosimilars Forum

Spotlight

Meitheal Announces Expansion of Portfolio of Generic Injectable Products

Spotlight

Meitheal Announces Exclusive Commercial Licensing Agreement for Insulin Biosimilars in the U.S.

Spotlight

Meitheal Announces Closing of Senior Secured Credit Facility Agreement for Up to $80 Million with J.P. Morgan

Spotlight

HealthTrust Performance Group Recognizes Suppliers of the Year for 2023

Spotlight

Astral SteriTech Pvt. Ltd. Recall

Spotlight

Xentria and Meitheal Pharmaceuticals announce exclusive licensing agreement for XTMAB-16 in North America

Spotlight

Meitheal is Ranked #4 on Crain’s 2023 Fast 50 in Chicago

Spotlight

Meitheal Pharmaceuticals Earns Great Place to Work Certification™ and Is Named One of Best Places to Work in Illinois

Spotlight

Meitheal Pharmaceuticals Announces Membership in The Association for Accessible Medicines

Spotlight

Meitheal Pharmaceuticals Announces Findings from Collaborative Research Study with Premier Inc. Evaluating Anticoagulant Treatment of COVID-19 Patients

Spotlight

Glycopyrrolate Recall

Spotlight

NKF and Meitheal Announce Dr. Jiali Luo as General Manager of New Biopharmaceutical Business

Spotlight

Meitheal Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of Cisatracurium Besylate Injection, USP 10mg per 5mL Due to Mislabeling

Spotlight
You might also be interested

Our Products

Slider image

Who We Are

Slider image
This Website Uses Cookies

This website uses cookies to help give you the best experience when you visit. By clicking “Accept Cookies,” you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and help us make improvements to our site. You can read more about our use of cookies in our Privacy Policy.

Manage Consent Preferences

Always Active

Necessary cookies enable core functionality such as security and accessibility. You may disable these by changing your browser settings, but this may affect how the website functions.

These cookies are set to provide quantitative measures of website visitors. Information collected with these cookies is used in operations to measure website performance. With the usage of these cookies we are able to count visits and traffic sources to improve our site. The data is collected in a way that does not directly identify anyone.
Accept all cookies Confirm my choices